Pliant Therapeutics Inc (PLRX)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Pliant Therapeutics Inc chart...

About the Company

pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

CEO

Bernard Coulie

Exchange

NASDAQ

Website

https://pliantrx.com/

$129M

Total Revenue

162

Employees

$875M

Market Capitalization

-5.29

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PLRX News

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

6d ago, source:

Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly ...

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

11d ago, source: Zacks.com on MSN

The market expects Pliant Therapeutics, Inc. (PLRX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known ...

Pliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid Financials

10d ago, source: Business Insider

Begin your TipRanks Premium journey today. Pliant Therapeutics (PLRX) Company Description: Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing ...

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

20d ago, source: Stockhouse

Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment ...

Pliant Therapeutics Inc Ordinary Shares

25d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pliant Therapeutics to Participate in Upcoming Investor Conferences

22d ago, source: Yahoo Finance

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

11d ago, source: Nasdaq

The market expects Pliant Therapeutics, Inc. (PLRX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known ...

Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

6d ago, source:

Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast's time to Phase 3 data Upsized Oxford Finance debt faci ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...